Prosecution Insights
Last updated: November 04, 2026
Application No. 18/533,474

REPLICATIVE MINICIRCLE VECTORS WITH IMPROVED EXPRESSION

Final Rejection §103§DOUBLEPATENT
Filed
Dec 08, 2023
Priority
Nov 19, 2012 — provisional 61/796,765 +6 more
Examiner
NGUYEN, QUANG
Art Unit
1631
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Aldevron L L C
OA Round
2 (Final)
38%
Grant Probability
At Risk
3-4
OA Rounds
1y 1m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants only 38% of cases
38%
Career Allowance Rate
286 granted / 756 resolved
-22.2% vs TC avg
Strong +53% interview lift
Without
With
+52.7%
Interview Lift
resolved cases with interview
Typical timeline
4y 0m
Avg Prosecution
45 currently pending
Career history
816
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
38.5%
-1.5% vs TC avg
§102
13.3%
-26.7% vs TC avg
§112
31.8%
-8.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 756 resolved cases

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Claims 1-9 and new claims 10-18 (presented in the Amendment dated 05/14/2026) are pending in the present application. Applicant’s election without traverse of SEQ ID NO: 20 as a species of RNA-OUT selectable marker in the reply filed on 08/21/2026 is acknowledged. Applicant also elected previously without traverse the following species: (i) the transgene is a target antigen for immunization; and (ii) the eukaryotic replicative pUC-free minicircle expression vector is introduced into the eukaryotic organism in a nanoparticle. Claims 3 and 5-7 were withdrawn previously from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected species. New claims 12, 14 and 16 were also withdrawn from further consideration because they were drawn to non-elected species. In light of the amendment to claim 6, previously withdrawn claim 6 was rejoined and examined herein with the above elected species. Accordingly, amended claims 1-2, 4, 6, 8-11, 13, 15 and 17-18 are examined on the merits herein with the above elected species. Response to Amendment 1. The rejection under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Williams (US 2010/0303859) in view of Lu et al (Mol. Ther. 20:2111-2119, Epub May 8, 2012) and Hyde et al (US 8,871,503) for claims 1-2, 4 and 8-9 was withdrawn in light of currently amended independent claim 1, particularly with the new limitation “a R6K bacterial replication origin having at least 95% sequence identity to SEQ ID NO: 11”. 2. The rejection on the ground of nonstatutory double patenting as being unpatentable over claims 1-5 of U.S. Patent No. 10,167,478 was withdrawn upon further consideration, particularly the R6K replication origin and an RNA selectable marker (e.g., RNA-OUT selectable marker) are in an intron comprising a 5’ splice donor and a 3’ splice acceptor branch site, wherein the intron is within a eukaryotic region with 5’ and 3’ ends encoding a gene of interest; and not in a spacer region linking the 5’ and 3’ ends of the eukaryotic region as recited in the claims of the present application. Claim Objections Applicant is advised that should claim 15 be found allowable, claim 17 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 608.01(m). Claim Rejections - 35 USC § 103 The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made. New claims 10-11, 13, 15 and 17-18 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Williams (US 2010/0303859) in view of Lu et al (Mol. Ther. 20:2111-2119, Epub May 8, 2012) and Hyde et al (US 8,871,503). This is a modified rejection necessitated by Applicant’s amendment. The instant claims encompass a method of expressing a transgene (e.g., a transgene encodes a target antigen for immunization, elected species) with a eukaryotic replicative pUC-free minicircle expression vector, the method comprising: introducing (e.g., via intramuscular or intradermal delivery) the eukaryotic replicative pUC-free minicircle expression vector into a eukaryotic organism under conditions sufficient to permit transfection of the eukaryotic replicative pUC-free minicircle expression vector into a cell of the eukaryotic organism and expression of the transgene, wherein eukaryotic replicative pUC-free minicircle expression vector comprises: (i) a eukaryotic region encoding the transgene having the transgene and having 5’ and 3’ ends, ii) a spacer region that links the 5’ and 3’ of the eukaryotic region, said spacer region comprising a R6K bacterial replication origin and a RNA-OUT selectable marker; wherein the RNA-OUT selectable has at least 95% sequence identity to the elected SEQ ID NO: 20; the same method wherein the eukaryotic replicative pUC-free minicircle expression vector is introduced into the eukaryotic organism in a nanoparticle (elected species). With respect to the elected species, Williams disclosed a family of improved eukaryotic expression plasmids useful for gene therapy, genetic immunization and/or interferon therapy in humans, other mammals, birds or fish, wherein the expression plasmids have reduced size, sequence content and antibiotic free selection (see at least the Abstract; Disclosure of the Invention; Brief Summary of the Invention; and paragraph 24). An exemplary immunostimulatory influenza H5 HA “bird flu” pDNAVACCultra plasmid (NTC8382-41H-HA) comprises a synthetic HA (vietnam1203) gene, an RNA-OUT selectable maker and an immunostimulatory RNA element (41H) cloned between the Eukaryotic terminator and the prokaryotic replication pUC origin (paragraphs 61, 95; and Figure 1). Williams also stated “In another preferred embodiment for therapy or vaccination, the RNA based selectable marker of the invention is incorporated into other DNA vaccine or therapeutic plasmid backbones, a non-limiting list includes VR1012, pVAX1, pVC0396, pCMVkm2, pITR, pCOR, pPJV7563, pWG4303 and derivatives” (last sentence of paragraph 96). It is noting that pCOR vector contains R6K gamma replication origin as evidenced at least by lines 13-14 at page 55 of the present application. An exemplary RNA-OUT selectable marker has the sequence of SEQ ID NO: 15 (139 bp) that is 100% identical to SEQ ID NO: 20 of the present application (paragraphs 184-185; Fig. 21 and attached sequence search below). Williams further disclosed the vector to be delivered to a cell in vivo, in vitro or ex vivo, utilizing one or more of the plurality of delivery methods known in the art that includes nanoparticles, microparticles, lipofection and others (paragraph 100). Williams also stated explicitly “For delivery to an organism, delivery may be by oral, buccal, nasal, inhalation, topical, vaginal, rectal, intravenous, intramuscular, intradermal, epidermal, systemic, or by other routes of administration known in the art” (last sentence in paragraph 100). Williams did not teach specifically a method of expressing a transgene with a eukaryotic replicative pUC-free minicircle expression vector into a eukaryotic organism, wherein the eukaryotic replicative pUC-free minicircle expression vector comprises: (i) a eukaryotic region encoding the transgene and having 5’ and 3’ ends, (ii) a spacer region that links the 5’ and 3’ ends of the eukaryotic region, said spacer region comprising a R6K bacterial replication origin and a RNA-OUT selectable marker. At the effective filing date of the present application (11/19/2012), Lu et al already taught that the length and not the sequence or the origin of the extragenic DNA flanking the expression cassette is responsible for plasmid-mediated transgene silencing, with shorter spacers ≤500 bp exhibited similar transgene expression patterns to conventional minicircle DNA vectors whereas DNA sequences of ≥1 kb in length resulted in transgene silencing (see at least the Abstract; section titled “Short plasmid BB sequences inserted as spacers are incapable of silencing transgene expression in vivo while longer plasmid BB sequences silence the transgene” and Figures 1-5). Lu et al stated “Previously, we have substituted various prokaryotic antibiotic resistance genes and/or various plasmid origins of replication, and eliminated non-essential plasmid BB sequences but transgene silencing still occurred regardless of the specific substitutions. In all cases, the plasmid BB was well over 1Kb" (bridging sentence between right col. on page 2113 to left col. on page 2114); and “[w]e constructed minicircles containing a 500 bp pUC-derived bacterial plasmid origin of replication in either the hFIX or hAAT expression cassette (Figures 3 and 4). As shown in Figures 3 and 4, 500 bp BB spacer failed to silence either the hAAT or hFIX transgene expression cassette in vivo. This result confirmed that generic plasmid origin sequence is not sufficient for transgene silencing in DNA plasmid vectors. On the other hand, when a fragment of a BB-a 1.5kb BB containing pUC origin and kanamycin resistance gene was placed in between the 5’ and 3’ ends of the hFIX expression cassette (MC.EF1α-hFIX-hGHpA-pUC-Kan (1.5kb)), transgene expression was silenced (Figure 5)” (connecting paragraph between right col. on page 2114 to left col on page 2115). Additionally, Hyde et al already disclosed the plasmid pGM160 (SEQ ID NO: 1) into which sequences can be cloned for expression from the hCEFI promoter for therapeutic application, along with the pGM151 (SEQ ID NO:2) and pGM144 (SEQ ID NO: 4) plasmids containing the coding sequences for the CFTR polypeptide and luciferase reporter polypeptide, respectively; with all of these plasmids contain an R6K origin of replication of about 300 basepairs (see Abstract; Summary of the Invention; particularly col. 11, line 62 continues to line 25 on col. 12; issued claims 1-8; and Figures 1-3). Hyde et al stated explicitly “The R6K origin is activated by the R6K specific initiator protein B encoded by the pir gene and hence constructs of the invention comprising the R6K origin will typically be grown in strains expressing the pir gene. Any suitable strain expressing the pir gene may be employed. In a preferred instance, constructs of the invention employing the R6K origin are grown in the E. coli strain GT115, EC100 Dpir-116 or DH10 Bpir116”, and “In a particularly preferred instance, the origin of replication may comprise the sequence of nucleotides 2599 to 2870 of SEQ ID No: 4, a functional fragment thereof, or a functional variant of either. The fragment and variants may be any of the lengths and possess any of the level of sequence identity specified herein” (col. 12, lines 3-17). Accordingly, it would have been obvious for an ordinary skilled artisan to modify the teachings of Williams by also expressing a transgene (e.g., a synthetic HA (vietnam1203) gene) in a mammal with an improved eukaryotic expression plasmid with reduced size, sequence content and antibiotic free selection that has an extragenic DNA spacer that is equal or less than 500 bp in length and comprising a non-pUC origin of replication such as the R6K replication origin and a RNA-OUT selectable marker; and wherein the spacer links the 5’ and 3’ end of a eukaryotic region comprising the transgene, in light of the teachings of Lu et al and Hyde et al as presented above. An ordinary skilled artisan would have been motivated to carry out the above modifications because Lu et al already taught at least that the length and not the sequence or the origin of the extragenic DNA flanking the expression cassette is responsible for plasmid-mediated transgene silencing, with shorter spacers ≤500 bp exhibited similar transgene expression patterns to conventional minicircle DNA vectors whereas DNA sequences of ≥1 kb in length resulted in transgene silencing. Lu et al also taught that generic plasmid origin sequence is not sufficient for transgene silencing in DNA plasmid vectors; and demonstrated that minicircles containing a 500 bp pUC-derived bacterial plasmid origin of replication in either the hFIX or hAAT expression cassette failed to silence either the hAAT or hFIX transgene expression cassette in vivo. Moreover, Hyde et al also disclosed successfully the use of plasmid constructs containing an R6K origin for therapeutic application. Furthermore, Williams teaches explicitly that other DNA vaccine or therapeutic plasmid backbones may be used not necessarily limited to a plasmid backbone with pUC ori, such as the pCOR vector containing the R6K gamma replication origin; and that intramuscular or intradermal administration can be used for vector delivery into an organism and the vector can also be in the form of nanoparticles for in vivo delivery. An ordinary skilled artisan would have a reasonable expectation of success in light of the teachings of Williams, Lu et al and Hyde et al; coupled with a high level of skill of an ordinary skilled artisan in the relevant art. The modified method resulting from the combined teachings Williams, Lu et al and Hyde et al is indistinguishable and it is encompassed by the claimed method of the present application. Since the modified method has the same method step (e.g., intramuscular or intradermal administration) and same starting materials (pUC-free minicircle expression vector with the recited limitations), such modified method would necessarily result in a transfection and expression of a transgene in a targeted cell. Therefore, the claimed invention as a whole was prima facie obvious in the absence of evidence to the contrary. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Amended claims 1-2 and 10-11 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-7 of U.S. Patent No. 10,047,365. Although the claims at issue are not identical, they are not patentably distinct from each other because a method of constructing a eukaryotic replicative pUC-free minicircle expression vector and expressing a transgene of interest (e.g., a target antigen transgene for genetic immunization; dependent claim 4) therefrom into a target eukaryotic cell or a eukaryotic organism, wherein the DNA sequence in a spacer region of less than 500 base pairs in length that encodes a R6K bacterial replication origin and a RNA-OUT selectable marker and linking the 5’ and 3’ ends of a eukaryotic region encoding a transgene of interest, having at least 95% sequence identity to SEQ ID NO: 26 (the sequence of nucleotides 32-312 in SEQ ID NO: 26 is 100% identical to SEQ ID NO: 11 of the present application; see attached sequence search below) and wherein said RNA-OUT selectable marker has at least 95% sequence identity to SEQ ID NO: 20 (dependent claim 6) in claims 1-7 in U.S. Patent No. 10,047,365 anticipates a method of expressing a transgene with a eukaryotic replicative pUC-free minicircle expression vector in the application being examined and, therefore, a patent to the genus would, necessarily, extend the rights of the species or sub- should the genus issue as a patent after the species of sub-genus. Amended claims 1-2, 4, 6, 8-11, 13, 15 and 17-18 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-7 of U.S. Patent No. 10,047,365 in view of Williams (US 2010/0303859). Claims 1-7 of U.S. Patent No. 10,047,365 encompass a method of constructing a eukaryotic replicative pUC-free minicircle expression vector and expressing a transgene of interest (e.g., a target antigen transgene for genetic immunization; dependent claim 4) therefrom into a target eukaryotic cell or a eukaryotic organism, wherein the DNA sequence in a spacer region of less than 500 base pairs in length that encodes a R6K bacterial replication origin and a RNA-OUT selectable marker and linking the 5’ and 3’ ends of a eukaryotic region encoding a transgene of interest, having at least 95% sequence identity to SEQ ID NO: 26 (the sequence of nucleotides 32-312 in SEQ ID NO: 26 is 100% identical to SEQ ID NO: 11 of the present application; see attached sequence search below) and wherein said RNA-OUT selectable marker has at least 95% sequence identity to SEQ ID NO: 20 (dependent claim 6) The instant claims of the present application differ from claims 1-7 of U.S. Patent No. 10,047,365 in reciting specifically that the eukaryotic replicative pUC-free minicircle expression vector is introduced into the eukaryotic organism via intradermal or intramuscular delivery and/or the eukaryotic replicative pUC-free minicircle expression vector is introduced into the eukaryotic organism in a nanoparticle. Before the effective filing date of the present application (11/19/2012), Williams already disclosed a family of improved eukaryotic expression plasmids useful for gene therapy, genetic immunization and/or interferon therapy in humans, other mammals, birds or fish, wherein the expression plasmids have reduced size, sequence content and antibiotic free selection (see at least the Abstract; Disclosure of the Invention; Brief Summary of the Invention; and paragraph 24). An exemplary immunostimulatory influenza H5 HA “bird flu” pDNAVACCultra plasmid (NTC8382-41H-HA) comprises a synthetic HA (vietnam1203) gene, an RNA-OUT selectable maker and an immunostimulatory RNA element (41H) cloned between the Eukaryotic terminator and the prokaryotic replication pUC origin (paragraphs 61, 95; and Figure 1). Williams further disclosed the vector to be delivered to a cell in vivo, in vitro or ex vivo, utilizing one or more of the plurality of delivery methods known in the art that includes nanoparticles, microparticles, lipofection and others (paragraph 100). Williams also stated explicitly “For delivery to an organism, delivery may be by oral, buccal, nasal, inhalation, topical, vaginal, rectal, intravenous, intramuscular, intradermal, epidermal, systemic, or by other routes of administration known in the art” (last sentence in paragraph 100). Accordingly, it would have been obvious for an ordinary skilled artisan to modify a method of constructing a eukaryotic replicative pUC-free minicircle expression vector and expressing a transgene of interest into a target eukaryotic cell or a eukaryotic organism in claims 1-7 of U.S. Patent No. 10,047,365 by also delivering a eukaryotic replicative pUC-free minicircle expression vector in the form of nanoparticles and/or via intramuscular or intradermal delivery into a eukaryotic organism; in light of the teachings of Williams as set forth above with a reasonable expectation of success. An ordinary skilled artisan would have been motivated to carry out the above modifications because Williams teaches a family of improved eukaryotic expression plasmids useful for gene therapy, genetic immunization and/or interferon therapy in humans, other mammals, birds or fish, wherein the expression plasmids have reduced size, sequence content and antibiotic free selection; and that intramuscular or intradermal administration can be used for vector delivery into an organism and the vector can also be in the form of nanoparticles for in vivo delivery. The modified method resulting from combining claims 1-7 of U.S. Patent No. 10,047,365 along with the teachings of Williams as set forth above is indistinguishable and it is encompassed by the claimed method of the present application. Therefore, the claimed invention as a whole was prima facie obvious in the absence of evidence to the contrary. In the Amendment filed on 05/14/2026 (last paragraph at page 6), Applicant simply stated that the above nonstatutory double patenting rejections are premature since no allowable subject matter indicated. Amended claims 1-2, 4, 6, 8-11, 13, 15 and 17-18 are rejected for the reasons set forth in the above nonstatutory double patenting rejections; and no Terminal Disclaimer has been filed. Conclusions No claim is allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Quang Nguyen, Ph.D., at (571) 272-0776. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s SPE, James Douglas (Doug) Schultz, Ph.D., may be reached at (571) 272-0763. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1633; Central Fax No. (571) 273-8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547. Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO’s Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll-free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO’s Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO’s PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. /QUANG NGUYEN/Primary Examiner, Art Unit 1631 Publication No. US20100303859A1 SEQ ID NO 15 LENGTH: 139 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: RNAOUT DraIII to KpnI selectable marker Query Match 100.0%; Score 139; Length 139; Best Local Similarity 100.0%; Matches 139; Conservative 0; Mismatches 0; Indels 0; Gaps 0; Qy 1 GTAGAATTGGTAAAGAGAGTCGTGTAAAATATCGAGTTCGCACATCTTGTTGTCTGATTA 60 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1 GTAGAATTGGTAAAGAGAGTCGTGTAAAATATCGAGTTCGCACATCTTGTTGTCTGATTA 60 Qy 61 TTGATTTTTGGCGAAACCATTTGATCATATGACAAGATGTGTATCTACCTTAACTTAATG 120 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 61 TTGATTTTTGGCGAAACCATTTGATCATATGACAAGATGTGTATCTACCTTAACTTAATG 120 Qy 121 ATTTTGATAAAAATCATTA 139 ||||||||||||||||||| Db 121 ATTTTGATAAAAATCATTA 139 Patent No. 10844388 SEQ ID NO 26 Query Match 100.0%; Score 281; Length 466; Best Local Similarity 100.0%; Matches 281; Conservative 0; Mismatches 0; Indels 0; Gaps 0; Qy 1 GGCTTGTTGTCCACAACCGTTAAACCTTAAAAGCTTTAAAAGCCTTATATATTCTTTTTT 60 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 32 GGCTTGTTGTCCACAACCGTTAAACCTTAAAAGCTTTAAAAGCCTTATATATTCTTTTTT 91 Qy 61 TTCTTATAAAACTTAAAACCTTAGAGGCTATTTAAGTTGCTGATTTATATTAATTTTATT 120 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 92 TTCTTATAAAACTTAAAACCTTAGAGGCTATTTAAGTTGCTGATTTATATTAATTTTATT 151 Qy 121 GTTCAAACATGAGAGCTTAGTACGTGAAACATGAGAGCTTAGTACGTTAGCCATGAGAGC 180 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 152 GTTCAAACATGAGAGCTTAGTACGTGAAACATGAGAGCTTAGTACGTTAGCCATGAGAGC 211 Qy 181 TTAGTACGTTAGCCATGAGGGTTTAGTTCGTTAAACATGAGAGCTTAGTACGTTAAACAT 240 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 212 TTAGTACGTTAGCCATGAGGGTTTAGTTCGTTAAACATGAGAGCTTAGTACGTTAAACAT 271 Qy 241 GAGAGCTTAGTACGTACTATCAACAGGTTGAACTGCTGATC 281 ||||||||||||||||||||||||||||||||||||||||| Db 272 GAGAGCTTAGTACGTACTATCAACAGGTTGAACTGCTGATC 312
Read full office action

Prosecution Timeline

Dec 08, 2023
Application Filed
Feb 17, 2026
Examiner Interview (Telephonic)
Feb 26, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT
May 14, 2026
Response Filed
Oct 28, 2026
Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760328
COMPOSITIONS AND METHODS FOR ALTERING GENE EXPRESSION
10y 0m to grant Granted Oct 13, 2026
Patent 12697350
METHODS AND COMPOSITIONS FOR TREATING A PREMATURE TERMINATION CODON-MEDIATED DISORDER
4y 3m to grant Granted Aug 04, 2026
Patent 12680074
ANTIGEN PRESENTING T CELLS, SENSITIZED, MANUFACTURED T CELLS AND METHODS OF TREATMENT USING THE SAME
3y 8m to grant Granted Jul 14, 2026
Patent 12680076
METHODS FOR ENGINEERING ALLOGENEIC AND HIGHLY ACTIVE T CELL FOR IMMUNOTHERAPHY
3y 8m to grant Granted Jul 14, 2026
Patent 12673116
COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECT
5y 3m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
38%
Grant Probability
90%
With Interview (+52.7%)
4y 0m (~1y 1m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 756 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month